Inotek Pharmaceuticals Corporation IPO Research Information

Inotek Pharmaceuticals Corporation IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Inotek Pharmaceuticals Corporation, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Inotek Pharmaceuticals Corporation	ITEK - NASDAQ	$13.00-$15.00	$6.00	$6.10	6.67 million	2/18/2015
Underwriter(s): Cowen & Co., Piper Jaffray
Co-Manager(s): Canaccord Genuity, Nomura
Industry: Health Care
Filing(s): Filed 2014-11-05 Terms Added 2015-01-22 Amended Terms 2015-02-17

Inotek Pharmaceuticals Corporation Quote & Chart - Click for current quote - ITEK

About Inotek Pharmaceuticals Corporation (adapted from Inotek Pharmaceuticals Corporation prospectus):
They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "ITEK" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.